Xeris Biopharma Holdings, Inc.

XERS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$71,621$67,449$121,966$67,271
Short-Term Investments$0$5,002$0$35,162
Receivables$40,415$39,197$30,830$17,456
Inventory$48,175$38,838$24,735$18,118
Other Curr. Assets$7,451$5,778$9,287$4,589
Total Curr. Assets$167,662$156,264$186,818$142,596
Property Plant & Equip (Net)$28,211$29,175$9,508$6,627
Goodwill$22,859$22,859$22,859$22,859
Intangibles$98,921$109,764$120,607$131,450
Long-Term Investments$4,123$0$0$0
Tax Assets$6,092$0$0$0
Other NC Assets-$4,808$4,540$4,730$829
Total NC Assets$155,398$166,338$157,704$161,765
Other Assets$0$0$0$0
Total Assets$323,060$322,602$344,522$304,361
Liabilities
Payables$2,290$11,565$4,606$8,924
Short-Term Debt$21,182$3,495$1,580$0
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$76,971$80,133$67,435$70,116
Total Curr. Liab.$100,443$95,193$73,621$79,040
LT Debt$250,265$225,696$196,477$88,067
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$2,268$3,518$4,942
Other NC Liab.$1,967$6,227$25,719$37,081
Total NC Liab.$252,232$234,191$225,714$130,090
Other Liabilities$0$0$0$0
Cap. Leases$39,339$38,259$10,982$0
Total Liabilities$352,675$329,384$299,335$209,130
Equity
Pref Stock$0$0$0$0
Common Stock$15$14$14$13
Retained Earnings-$671,861-$617,025-$554,770-$460,110
AOCI-$25-$25-$23-$31
Other Equity$642,256$610,254$599,966$555,359
Total Equity-$29,615-$6,782$45,187$95,231
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$323,060$322,602$344,522$304,361
Net Debt$199,826$161,742$76,091$20,796